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Abstract
Commercial seasonal flu vaccines induce production of antibodies directed mostly towards hemaglutinin (HA). Because HA
changes rapidly in the circulating virus, the protection remains partial. Several conserved viral proteins, e.g., nucleocapsid
(NP) and matrix proteins (M1), are present in the vaccine, but are not immunogenic. To improve the protection provided by
these vaccines, we used nanoparticles made of the coat protein of a plant virus (papaya mosaic virus; PapMV) as an
adjuvant. Immunization of mice and ferrets with the adjuvanted formulation increased the magnitude and breadth of the
humoral response to NP and to highly conserved regions of HA. They also triggered a cellular mediated immune response
to NP and M1, and long-lasting protection in animals challenged with a heterosubtypic influenza strain (WSN/33). Thus,
seasonal flu vaccine adjuvanted with PapMV nanoparticles can induce universal protection to influenza, which is a major
advancement when facing a pandemic.
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Introduction
Influenza epidemics cause between 250,000 and 500,000 deaths
every year worldwide (http://www.who.int/en/). Many of these
deaths could be prevented by vaccination programs but vaccine
producers are currently unable to keep up with increasing demand and
the need for new vaccines. Most seasonal vaccines against influenza are
based on trivalent inactivated vaccine (TIV), which induces an
antibody response towards the highly variable surface glycoproteins
hemagglutin (HA) and neuraminidase (NA) [1]. The effectiveness of
neutralizing antibody generated by these vaccines declines over time as
circulating viruses accumulate mutations in response to immune
pressure [2]. As a consequence, the immunity engendered by TIV is
partial, as it offers no protection against antibody-escaped variants or
new pandemic influenza A viruses originating from non-human
reservoir [3,4,5]. Other issues that limit the utility of TIV include the
lack of a reliable method to estimate future influenza evolution, and the
long lead time between the selection of vaccine strains and release of
vaccine onto the market, which could help explain the high degree of
mismatch between circulating and vaccine strains. Current vaccine
production is also constrained by the absolute requirement for
specialized egg-based production facilities [6].
Recent human infection by porcine A (H1N1) subtype and the
highly pathogenic avian A (H5N1) influenza virus has led to
renewed interest in the development of universal vaccines that
would confer heterosubtypic immunity regardless of subtype or
strain. Such cross-protective immunity is induced to some extent
during natural infection, and is mediated mainly by CD8+
cytotoxic T lymphocytes (CTL), which recognize conserved
internal components of the virus and cross reactive antibody [7–
12]. This immune response can promote early virus elimination
and decrease morbidity [13]. Unfortunately, commonly used
inactivated vaccines do not induce CTL efficiently. Addition of
adjuvant is one possible option to enhance the immunogenicity
and efficiency of conventional vaccines [14].
In this study, we evaluated the capacity of nanoparticles made of
papaya mosaic virus (PapMV) coat protein (CP) to act as an
adjuvant for TIV. The expression of PapMV CP in bacteria leads
to self-assembly and formation of virus-like particles (VLP, or
nanoparticles) composed of several hundred recombinant CP
subunits organized in a repetitive and ordered manner [15].
PapMV Nanoparticles can be used as an epitope display system
that is very immunogenic, even in the absence of external adjuvant
and lead to production of antibodies directed towards the surface-
exposed peptide, thus providing protection [16,17]. Engineered
PapMV nanoparticles with CTL epitopes induce efficient cross
presentation of the epitope on MHC class I [18], and induce
protection against viral infection [19]. Based on this strong
immunogenicity of PapMV nanoparticles, we evaluated their
specific capacity to improve TIV efficacy, as well as their potential
use as an adjuvant for seasonal influenza vaccines.
Results
PapMV nanoparticles are recognized by immune cells
and transported to lymph nodes
We produced PapMV nanoparticles comprised of PapMV CP
using the bacterial expression vector pET-3D (Novagen) as
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single, homogenous protein of 30 kDa (Figure S1A) that self-
assembled into nanoparticles (Figure 1A) with an average length of
70 nm as measured by dynamic light scattering (DLS) (Figure S1B).
We previously reported that PapMV nanoparticles, alone or fused to
a peptide, are immunogenic [16,17] and are taken up by dendritic
cells [19]. To illustrate the speed of capture of PapMV nanoparticles
by immune cells, we injected labeled nanoparticles into the footpad of
Balb/C mice. The proximal popliteal lymph node became
fluorescent 24 hours after injection (Figure 1B). The signal declined
progressively over the subsequent 48 hours, suggesting that the
nanoparticles are rapidly degraded. We also evaluated the cytokine/
chemokine profile secreted by spleen cells following one or two
subcutaneous injections into the back of the neck of these animals.
Reactivation of spleen cells of mice immunized once led to the
secretion of MIP-1a and mKC (Figure 1C). We measured lower but
significant amounts of IL-6, G-CSF, TNF-a,I L - 2 ,R A N T E S ,M C P -
1, IL-1a, Il-5, IFN-c and IL-17 in these mice. Two immunizations
also led to an increase in MIP-1a and mKC levels, as well as
abundant secretion of IL-2, 5 and 6(Figure 1D).Lower but significant
levels of IL-13, G-CSF, GM-CSF, IFN-c,I l - 1 0 ,I L - 1 a,R A N T E S ,
MCP-1, IL-17, TNF-a and Il-4 were also detected. This result
suggests that PapMV nanoparticles are perceived efficiently by the
immune system and trigger secretion of a balanced TH1/TH2
cytokine profile. PapMV VLP could thus be considered as a
pathogen-associated molecular pattern (PAMP) that can be poten-
tially used as an adjuvant for improvement of TIV.
Improvement of TIV humoral response using PapMV
nanoparticles
To test our hypothesis, we set up an immunization program
with TIV (2007–2008) alone or adjuvanted with either 3 or 30 mg
of PapMV nanoparticles. Balb/c mice (5/group) were immunized
twice by the subcutaneous route with a 2-week interval. The
humoral response against TIV and purified recombinant GST-NP
(Figure 2) was measured by ELISA. The recombinant GST-NP
antigen used for the ELISA is derived from the influenza strain
WSN/33 (Figure S2).
The addition of 30 mg PapMV nanoparticles was more efficient
than 3 mg in improving the humoral response to TIV (2007–2008);
we measured a 3.5-fold increase in the amount of total IgG
(Figure 2A), and a 8-fold increase in IgG2a isotype directed
towards TIV (2007–2008) antigen (Figure 2B). Interestingly, the
amount of isotype IgG1 was not significantly improved by the
presence of PapMV nanoparticles (Figure 2C).
TIV (2007–2008) is composed of split influenza virus that
contains the structural protein NP. The NP component of TIV is
not very immunogenic but the addition of the PapMV
nanoparticles increased the immune response directed to this
highly conserved influenza antigen by 36 fold (Figure 2D), thus
showing that PapMV nanoparticles improve the TH1 immune
response directed towards the conserved influenza structural
protein NP. These results suggest that, in contrast to alum, which
is unable to improve the immune response of TIV (Figure S3),
PapMV nanoparticles induce a TH1 response to TIV.
We repeated this experiment using a similar immunization
protocol using TIV (2008–2009) and TIV (2009–2010), which
contains different strains of influenza, to show that PapMV
nanoparticles can act as an effective adjuvant for any TIV. As
expected, we observed a significant increase in total IgG (.3x),
and IgG2a (.4x) directed towards TIV (2008–2009) (Figure S4A–
B). PapMV nanoparticles also improved significantly IgG2a
directed to the conserved protein NP (.16x) (Figure S4C). With
TIV (2009–2010), we showed improvements in total IgG (.8x)
(Figure S5A) and IgG2a (16x) (Figure S5B) directed to TIV (2009–
2010), as well as total IgG titers directed towards the pandemic
influenza vaccine 2009 (Figure S5D). Furthermore, IgG2a directed
towards GST-NP were detected only in the adjuvanted group
(Figure S5C).
To confirm this result in another animal model, we immunized
ferrets (6 per group) twice with a 3-week interval with one human
dose of TIV (2009–2010) alone or adjuvanted with 150 mgo f
PapMV nanoparticles. We showed that PapMV nanoparticles
improved the total IgG titers to TIV (2009–2010) already after one
immunization (Figure 3A), reaching a significant 4-fold increase
after one booster (Figure 3B). The ELISA against TIV (2008–
2009), which contains related but distinct strains of influenza,
using the same serum showed a tendency towards improvement in
the presence of the adjuvant (p, 0.1652) (Figure 3C). Similarly,
we notice a tendency towards improvement of the IgG response to
GST-NP (p, 0.1383) (Figure 3D), which is consistent with the
results obtained in mice. The lack of significant difference in the
average of the two last groups is probably related to the small
number of animals per group used in the experiment. Interest-
ingly, we noticed a significant difference in the variance between
the non adjuvanted and the adjuvanted group in the amount of
IgG directed to the GST-NP protein (Figure 3D).
To demonstrate the capacity of PapMV nanoparticles to
improve the humoral response to conserved epitopes located on
the surface glycoproteins of influenza, we performed ELISA with
the serum generated from the immunization protocol with TIV
(2008–2009) and 30 mg PapMV nanoparticles toward the hetero-
subtypic mouse-adapted strain WSN/33 (H1N1) or the horse
strain A/Kentucky/91 (H3N8). Intact virus was used to coat the
ELISA plate, restricting the epitopes available for binding
antibodies to the HA and NA proteins located at the surface of
the virus. Interestingly, 6 out of 10 mice in the adjuvanted groups
reacted to the WSN/33 coating (Figure 4A), and 9 out of 10 sera
reacted to the horse A/Kentucky/91 (H3N8) strain (Figure 4B). A
similar observation was made with the serum of mice vaccinated
with adjuvanted TIV (2009–2010), with the amount of IgG able to
cross react with the pandemic H1N1 Flu vaccine being increased
32 fold (Figure S5D). The cross reactivity of the serum of the
adjuvanted mice suggests that PapMV nanoparticles are able to
increase the breadth of the humoral response to include epitopes
that are common to heterosubtypic strains that are unrelated to
the strain present in the vaccine.
To confirm that use of the adjuvant increases the breadth of the
humoral response to conserved epitopes of HA, we performed an
immunoblot on 56 peptides of 15 amino acids in length
overlapping each other by 5 amino acids, and covering the entire
amino acid sequence of WSN/33 HA. The peptides were spotted
onto a glass plate and hybridized with serum of ferrets immunized
with TIV alone or adjuvanted with PapMV nanoparticles. A very
weak signal on a few peptides was obtained when the peptides
were hybridized with pre-serum or with serum of ferrets
immunized with TIV (2009–2010)(Figure S6). When using serum
of animals vaccinated with adjuvanted vaccine, we considered
positive signals to be those at least 3 fold higher than the
background obtained with pre-serum or serum obtained from
animals vaccinated with TIV (2009–2010) alone. We found that
three additional peptides were recognized only by the adjuvanted
ferret serum (Figure 5A). The location of these three regions
corresponds to HA 200–225 and HA 290–325—conserved regions
that are common to the H1N1 strain Brisbane/59/07 found in
TIV (2009–2010) and the WSN/33 mouse-adapted strain
(Figure 5B). These same regions are also common to the H1N1
pandemic strain of 2009 and the H1N1 pandemic strain of 1918.
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sequence of HA—a region known to be a good target for the
development of a universal influenza vaccine [20].
PapMV nanoparticles increase secretion of IFN-c by T
lymphocytes
The induction of high levels of IgG2a to conserved antigens of
TIV by PapMV nanoparticles suggests that the adjuvant induces a
TH1 response. To verify the efficacy of the adjuvant to improve
secretion of IFN-c—a good TH1 marker—we performed an
ELISPOT assay using the highly conserved influenza proteins M1
and NP to reactivate T lymphocytes. As before, Balb/c mice (5/
group), were vaccinated with TIV (2008–2009) alone or with
PapMV nanoparticles. Splenocytes were collected 14 days after
the boost. The ELISPOT assay showed a significant increase in
the number of T cells secreting IFN-c in the adjuvanted groups
when reactivated with GST-NP (Figure 6A) or GST-M1
(Figure 6B), which supports the hypothesis that PapMV nanopar-
ticles trigger a CTL response.
PapMV nanoparticle adjuvant induces protection from
infection with a heterosubtypic strain
The immunological characterization presented above shows
that using PapMV nanoparticles as an adjuvant can trigger a TH1
Figure 1. PapMV nanoparticles and the secretion of TH1/TH2 cytokines. A, Observation of adjuvant PapMV nanoparticles by electron
microscopy. Bar 0.2 mm. B, In vivo imaging of fluorescently labeled PapMV nanoparticles. Data are presented as pseudocolor images indicating
fluorescence (Alexa@680) intensity, with a gradation from red (more intense) to yellow, superimposed over gray-scale reference photographs of the
left inferior member of the treated mouse. Images were taken at 24, 48 and 72 h post-injection. The proximal popliteal lymph node is indicated with a
dotted circle. At 24 h, a strong signal is detected in the foot pad of the animal where the fluorescent protein was injected. C,D Cytokine/chemokine
profile of splenocytes reactivated with PapMV nanoparticles (100 mg/ml) isolated after one (C) or two (D) subcutaneous immunizations.
doi:10.1371/journal.pone.0021522.g001
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1/5 of the human dose of trivalent inactivated vaccine (TIV) (2007–2008) alone or with PapMV nanoparticles (3 or 30 mg). IgG titers were evaluated by
ELISA 14 days after immunization. a–c Response to TIV (2007–2008): A, Total IgG, B, IgG2a and C, IgG1. D, IgG2a response to a recombinant GST-NP
(A/WSN/33-H1N1). * p, 0.05, ** p, 0.01 and *** p, 0.001.
doi:10.1371/journal.pone.0021522.g002
Figure 3. PapMV nanoparticles improve the humoral response of TIV (2009–2010) in ferrets. Male ferrets (6 per group) were immunized
twice with a 3-week interval with a human dose of TIV (2009–2010) alone or with PapMV nanoparticles (150 mg). Serum IgG titers were evaluated by
ELISA after 21 days. A, total IgG to TIV (2009–2010) after one immunization; B, total IgG to TIV (2009–2010) after two immunizations; C, total IgG to
TIV (2007–2008); D, total IgG to a recombinant GST-NP (A/WSN/33-H1N1).
doi:10.1371/journal.pone.0021522.g003
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M1) that extends the humoral response to conserved regions of the
HA protein found on heterosubtypic strains of the virus. It is
therefore expected that PapMV nanoparticles will improve the
protection afforded TIV from infection with a heterosubtypic
strain of influenza. To test this hypothesis, we immunized mice
twice with TIV (2008–2009) from two different commercial
sources, alone or adjuvanted with 30 mg of PapMV nanoparticles.
The mice were then challenged with the mouse-adapted strain
WSN/33. We found that mice treated with the adjuvanted vaccine
did not lose weight (Figure S7A), showed no viral symptoms
(Figure S7B) and were afforded 100% protection (Figure 6C)
compared to mice vaccinated with TIV alone, which were strongly
affected by infection with WSN/33.
To see if a memory response was induced by the adjuvant, we
immunized mice once with TIV (2007–2008) alone or with TIV
adjuvanted with 30 mg of PapMV nanoparticles and performed
the challenge 10 months after immunization. The improvement in
the immune response in the adjuvanted groups was maintained
even 10 months after the immunization (Figure S8A–C). Upon
challenge with the WSN/33 strain, we observed no weight loss (see
Figure S8D) or symptoms (Figure S8E), and 100% of the animals
immunized with the adjuvanted vaccine (Figure 6D) were
protected, in contrast with mice vaccinated with TIV alone,
which showed only 20% survival (Figure 6D).
Finally, to monitor the importance of the CD8+ mediated
immune response to protection induced by PapMV nanoparticles
adjuvant, we immunized mice (10/group) with TIV (2008–2009)
alone, 2 groups with TIV (2008–2009) adjuvanted with 30 mgo f
PapMV nanoparticles and one control group with saline. One of
the adjuvanted groups was further treated at days -3 and -1 before
infection with WSN/33 with a monoclonal antibody directed
towards CD8 to deplete CTL. Infection of the immunized mice
with WSN/33 revealed that CTL depletion affected the protection
observed in the adjuvanted groups partially but significantly
(Figure 6E). Depletion of CD8+ had a minor effect on weight loss
(Figure S9A) but enhanced the symptoms induced by the infection
(Figure S9B). An imperfect but significant correlation between the
levels of IgG directed to WSN/33 virus and protection was
observed, suggesting that antibodies might play an effective role in
protecting mice from the challenge (Figure S9C).
Discussion
The efficiency of TIV immunization decreases as the mismatch
between the vaccine strain and the circulating strain increases [3–
5]. The use of adjuvants in vaccines is an attractive approach to
increasing the cross-reactivity of influenza vaccines [21). It is
widely accepted that protection against seasonal influenza
correlates highly with the level of serum antibodies, which are
directed mainly against HA protein. Using PapMV nanoparticles
as an adjuvant, we increased the global humoral response through
the increase of total IgG titers, and particularly the IgG2a subclass
against TIV. IgG2a is more effective in preventing intracellular
virus replication since it is more efficient in complement activation
and antibody-dependent cellular immunity [22,23]. This different
activation capacity can be explained by the stronger affinity of
IgG2a for the complement [24,25] and Fc receptor [26,27] than
the IgG1 subclass. For the reasons stated above, TH1-type and
IgG2a-dominated humoral responses are preferred over TH2-type
responses for protection against influenza infection [26,28]. Other
adjuvants have been shown to increase the antibody response to
flu vaccines, but many of them, like MF-59, have a bias towards
TH2 rather than the TH1-like response promoted by PapMV
nanoparticles [21]. This data is consistent with the profile of
cytokines and chemokines that were induced in splenocytes
stimulated with PapMV nanoparticles, where abundant pro-
inflammatory cytokines (MIP-1a and KC), TH1 (IL-2) and TH2
cytokines (IL-5, IL-6) were induced.
Our immunoblot analysis demonstrated that PapMV nano-
particles increased the breadth of the antibody response to HA as
previously shown for MF-59 [29]. A recent study on HIV
antigens adsorbed on particulate adjuvant showed that surface
rearrangement of the target protein leads to unmasking of cryptic
epitopes, which is important for protection against heterosubtypic
strain [30]. The same phenomenon was observed using PapMV
nanoparticles as an adjuvant in mice and ferrets. Antibodies
directed towards a highly conserved pocket in the stem region of
HA containing the fusion peptide were revealed using PapMV
nanoparticles. Such an antibody has been shown to block
infection by inserting its heavy chain into this region, and this
could potentially interfere with membrane fusion rather than cell
attachment [20]. Recent studies with monoclonal antibodies have
shown that a domain in the stalk region of HA is conserved across
a number of subtypes [31,32] and is protective against lethal
challenge of H5N1 and H1N1 in mice. The improvement in the
antibody response with PapMV nanoparticles correlates with the
protection against a heterosubtypic strain, which can also be
attributed to a cross reaction with conserved epitopes on the
surface of infected cells that could be useful in the control of
infection via an antibody-mediated cellular response [33,34].
The use of PapMV nanoparticles also increased the IFN-c
mediated immune response against highly conserved influenza
proteins within different subtypes, such as NP and M1 [35,36].
Figure 4. PapMV nanoparticles increase the breadth of the humoral response directed towards TIV (2008–2009). Balb/C mice (10 per
group) were immunized once with 1/5 of the human dose of TIV (2007–2008) alone or with 30 mg PapMV nanoparticles. A, Total IgG directed
towards intact virion of influenza strain WSN/33. B, Total IgG directed to intact virion of the strain A/Kentucky/91 (H3N8). * p, 0.05 and *** p, 0.001.
doi:10.1371/journal.pone.0021522.g004
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towards an internal protein of the virus particle can contribute
to protection from influenza challenge via the involvement of
complement and antibody dependent cellular mechanisms [37–
40]. In this study, we measured increased protection against a
distant heterosubtypic strain (WSN/33) resulting from the use
of the adjuvant. Protection was still efficient even 10 months
after immunization. Heterosubtypic protection is mediated by
both CD4+ and CD8+ T cells, and is directed mostly against
internal viral proteins, although the CD8+ subset is generally
considered to be more important [41,42]. In the present study,
results from CD8+ cell depletion experiments suggest that
CD8+ T cells play an important role in the enhanced
protection observed.
One of the main concerns surrounding the use of adjuvants is
the potential toxicity of these molecules, which is usually related to
the development of local reactions due to the induction of a strong
inflammatory response [43]. In most cases, inflammation is
associated with secretion of TNF-a, which is linked with the
development of pain [44–46]. The cytokine/chemokine profile of
PapMV nanoparticles does not indicate any significant induction
of TNF-a. This might suggest that injection of the adjuvant is
painless. This is consistent with our observations; mice and ferrets
immunized with PapMV nanoparticles did not show any signs of
discomfort. PapMV nanoparticles can thus be viewed as a novel
type of painless adjuvant inducing a balanced TH1/TH2 immune
response. Because PapMV nanoparticles are produced in bacteria
at a very high yield, we believe that this adjuvant has very
Figure 5. Summary of the immunoblot analysis using serum of ferrets immunized with TIV alone or with PapMV nanoparticles. A,
Schematic representation of HA protein sequence and position of the different 15-aa peptides on the HA sequence. Small gray rectangles represent
peptides that reacted exclusively with serum of ferrets immunized with TIV (2009–2010) + 150 mg PapMV nanoparticles, or peptides that reacted only
with serum of mice immunized with TIV (2008–2009) + 30 mg PapMV nanoparticles. Black rectangles represent the extent of peptides that reacted in
both species. B, Amino acid sequence alignment of peptidic regions that reacted with serum of both species. A/Brisbane/59/07 is the H1N1 vaccine
strain, A/WSN/33 is the mouse-adapted strain, A/California/04/09 is the 2009 pandemic strain, and A/Brevig Mission/1/1918 is the Spanish flu strain.
Identical amino acids are in bold and underlined. A conserved region of HA is boxed.
doi:10.1371/journal.pone.0021522.g005
Improvement of Flu Vaccine Using PapMV
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21522promising potential because it can be produced in large quantities
at a competitive cost.
The heterosubtypic protection that we observed could have
been mediated through cross-reactive antibodies [12] and/or by
influenza specific CD8+ T cells [11]. Several DNA vaccine studies
have demonstrated that vaccination combining HA with DNA
encoding internal proteins was more effective than immunization
with individual plasmid alone [47–49]. A recent H5N1 DNA
vaccine study in a mouse model showed that a combination of
HA-antibody and a CD8+ CTL response directed against a
specific NP epitope resulted in reduced inflammation severity and
lung viral titers compared to mice in which only one arm of the
immune system was activated [50]. However, DNA vaccines are
not very efficient in large animals and need sophisticated
electroporation technology to be used in humans, which is not
compatible with broad vaccination campaign. The use of the
PapMV nanoparticles is simple and does not require sophisticated
equipment. PapMV nanoparticles need only to be added to the
TIV before injection to benefit from an improved immune
response. The effectiveness of the dose can be significantly
augmented (4 fold), as well as the efficacy and the memory
response of the vaccine toward heterosubtypic strains. In the case
Figure 6. PapMV nanoparticles trigger a CTL response to conserved influenza epitopes. Balb/C mice (5 per group) were immunized twice
with a 14-day interval with 1/5 of the human dose of TIV (2009–2010) alone or with 30 mg of PapMV nanoparticles. Spleens were collected 14 days
after the boost. We used purified recombinant GST-NP (A) or GST-M1 protein derived from the WSN/33 strain (B) to perform an ELISPOT assay. * P
,0.05. (C) PapMV nanoparticles improve survival to a sub-lethal challenge with a heterosubtypic strain. Balb/C mice (10 per group) were immunized
with TIV (2008–2009) from two different companies (#1 or 2) alone or with 30 mg of PapMV nanoparticles. Mice were challenged with 1LD50 of
A(H1N1)/WSN/33 influenza virus, 2 weeks after the final boost and were followed for a 14-day period. (D) A similar protocol was also followed with
mice immunized once with TIV (2007–2008) alone or adjuvanted with 30 mg PapMV nanoparticles except that the infection with the heterosubtypic
strain WSN/33 was performed 10 months after the immunization. (E) A immunization protocol similar to that described in c was performed with TIV
(2008–2009) alone or adjuvanted with 30 mg of PapMV nanoparticles. The depletion of CD8+ cells was performed at days -3 and -1 before the
challenge and 14 days after the boost.
doi:10.1371/journal.pone.0021522.g006
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nanoparticles as an adjuvant to improve the protection afforded
by the seasonal flu vaccine toward heterosubtypic strains to ensure a
rapid protection of the population during the time needed to produce
a new vaccine adapted to the pandemic strain. Once the pandemic
vaccine is obtained, PapMV nanoparticles could continue to be used
to decrease the doses of vaccine required and to augment coverage.
To our knowledge, this is the first report describing the adjuvant
property of plant-virus-derived nanoparticles.
Materials and Methods
Ethics Statement
All the work with animals has been done with Institution
approved ethics protocol by the ’Comite ´ de Protection des
Animaux - CHUQ (CPA-CHUQ). The approval of this project
is found under the authorization number 2010148-1.
Production of PapMV nanoparticles
Expression and purification of PapMV nanoparticles were
performed as described previously [17]. LPS contamination was
always less than 5 endotoxin (EU) units/mg of protein. The size
and structure of the nanoparticles were confirmed by observation
on a TEM (JEOL -1010, Tokyo, Japan) and dynamic light
scattering (DLS) (Zetasizer Nano ZS, Malvern, Worcestershire,
UK) microscope.
In vivo fluorescence imaging
Nanoparticles were labeled with Alexa@680 (Invitrogen,
Burlington, ON, Canada) and injected (25 mg) into the footpad
of 3 anesthetized Balb/C mice. Three other mice were injected
with Alexa@680 staining as negative control. The images were
gathered with an IVIS 200 imaging system (Xenogen, Alameda,
CA, USA) at 24, 48 and 72 hours. The data are represented as
pseudocolor images indicating fluorescence intensity (red and
yellow, most intense).
Cytokine/chemokine profile
Mice (Charles River, Wilmington, MA) were immunized (2
groups of 5 Balb/C mice) with 30 mg of PapMV nanoparticles
once or twice at 2-week intervals. Splenocytes, 2.5610
5 cells/well
were reactivated with either culture medium or nanoparticles and
cultured for 36 h. The cytokines and chemokines were evaluated
with MILLIPLEX MAP Mouse Cytokine/Chemokine - Premixed
22 Plex (Millipore, Billerica, MA, USA) for LuminexH xMAPH
platform. Measurements were performed with a Luminex 100IS
liquichip workstation (Qiagen, Canada).
Immunization
Mice, five to ten Balb/C mice per group (Charles River,
Wilmington, MA) were injected s.c. with 1/5 of the human dose
of the seasonal (Fluviral; Glaxo Smith Kline) TIV (2007–2008;
A/Solomon Islands/3/2006 (H1N1): A/Wisconsin/67/2005
(H3N2) and B/Malaysia/2506/2004), TIV (2008–2009; A/
Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and
B/Florida/4/2006) or TIV (2009–2010; A/Brisbane/59/2007
(H1N1), A/Brisbane/10/2007 (H3N2) and B/Brisbane/60/
2008) alone or adjuvanted with 3 mgo r3 0 mgo fP a p M V
nanoparticles. We also used the TIV (2008–2009) (Influvac) from
Solvay. The animals were given two immunizations at 14–day
intervals. Blood samples were collected at days 14 and 28. Ferrets
were immunized twice at 3-week intervals with one human dose
of TIV (2009–2010) alone or with 150 mg of PapMV nanopar-
ticles by the intramuscular route. Blood was recovered 21 days
after each immunization.
Antibody titration by ELISA
ELISA was performed as previously described (11) using the
following antigens: TIV at 0.1 mg/ml, GST-NP at 1 mg/ml, A/
WSN/33 virions at 0.1 mg/ml, A/Kentucky/91(H3N8) virions
(Flu Avert; Intervet) vaccine at 1 mg/ml. The GST-NP and GST-
M1 antigens were produced through a C-terminal GST fusion
with the NP and the M1 gene of the WSN/33 influenza strain and
affinity purified.
Immunoblot of WSN/33 HA overlapping peptides
A NexterionH Slide AL from Microarray Solutions SCHOTT
North America Inc. (Louisville, KY, USA) was used to spot 56
overlapping WSN/33 HA peptides (synthesized by GeneScript,
Piscataway, NJ, USA) in duplicate. Slides were blocked with PBS
+ 0.05% TweenH 20 (PBST) + 1% BSA for 1 hr at RT. Testing
(TIV + nanoparticles immunized ferrets) and control serums
(TIV alone immunized ferrets) were added to the wells and
incubated for 1 h30 at RT. Wells were washed three times for 3
minutes each with PBST. Alexa fluor 647 anti-IgG ferret at
20 mg/ml (anti-IgG ferret [Bethyl, cat#A140-108P] were added
and incubated at RT for 1 hr, followed by four washes with
PBST. The slides were dried and scanned with the apparatus
ScanArray 4000XL (GSI Lumonics) and images were analyzed
with GenePix Pro. Ratio F555 mean normalized = mean (signal
intensity of the testing serum– background around the dot)/
normalization signal mean (signal intensity of the control serum -
background around the dot). A ratio F555 $3 was considered a
positive signal.
Splenocyte isolation and ELISPOT assays
The day before splenocyte isolation, ethanol (70%)-treated
MultiScreen-IP opaque 96-well plates (High Protein Binding
Immobilon-P membrane, Millipore, Bedford, MA) were coated
o v e r n i g h ta t4 uCw i t h1 0 0ml/well of capture IFN-c antibody,
diluted in DPBS (Abcam, Cambridge, MA, USA). Two weeks
after the boost, mouse spleen cells were isolated. The precursor
frequency specific T cells was determined by subtracting the
background spots in media alone from the number of spots seen
in response to the different activators.
Influenza A and challenge
The influenza virus A strain used in this study is A/WSN/33
(H1N1). Mice were infected by the intranasal route using 50 ml
containing 1LD50. Mice were monitored daily for clinical
symptoms (loss of body weight, abnormal behavior and ruffled
fur). Deaths were recorded over a period of 14 days.
CD8+ T-cell depletion
For T-cell depletion, we injected mice with 0.1 mg i.p. of
monoclonal antibodies directed to CD8+ in vaccinated mice at
day 33 and 35. After depletion, validated by FACS, mice were
challenged as before on day 36.
Statistical analysis
Data were analyzed with parametric (or non parametric when
the variance were significantly different) ANOVA test. Tukey’s
post tests were used to compare differences (antibody titers,
ELISPOT) among groups of mice. Differences among survival
curves were analyzed by Kaplan–Meier survival analysis. Values
of *p , 0.05, **p , 0.01, ***p , 0.0001 were considered
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GraphPad PRISM 5.01.
Supporting Information
Figure S1 Purification of the PapMV CP from bacteria.
A, SDS-PAGE purification of PapMV CP over-expressed in E. coli.
Lanes: 1 Broad range protein marker, 2 bacterial lysate before
induction, 3 bacterial lysate after induction, 4 purified PapMV CP
after elutionB, Size distribution ofPapMVnanoparticlesas measured
by dynamic light scattering (DLS) showing a peak at 70 nm.
(TIF)
Figure S2 SDS-PAGE purification profile of GST-NP.
The NP gene of the influenza strain WSN/33 was cloned in fusion
with the C-terminus of GST. GST-NP was expressed in E. coli.
GST-NP was used to evaluate the antibody titer to NP by ELISA
and IFN-c secretion by ELISPOT. Lanes: 1 Broad range protein
marker, 2 bacterial lysate before induction, 3 bacterial lysate after
induction, 4 purified GST-NP after elution.
(TIF)
Figure S3 Alum as an adjuvant of TIV (2007–2008). Balb/
C mice (10 per group) were vaccinated once (s.c.) with 1/5 of the
human dose of the TIV (2007–2008) or adjuvanted alum. Serum was
collected 14 days after immunization. Total IgG (A) or the IgG2a
subtype (B) were measured by ELISA against TIV (2007–2008).
(TIF)
Figure S4 PapMV nanoparticles improve the humoral
response of TIV (2008–2009). Balb/C mice (10 per group)
were vaccinated twice with a 14-day interval with 1/5 of the human
dose of TIV (2008–2009) adjuvanted with 30 mg PapMV
nanoparticles. Serum collected 14 days after the boost was analyzed
by ELISA, measuring total IgG titers (A) and IgG2a titers (B)
directed towards TIV (2008–2009). IgG2a titers directed towards
purified recombinant GST-NP [A/WSN/33 (H1N1)] were also
measured (C). * p, 0.05,** p, 0.01, *** p, 0.001. Numbers
(.3X, .4X, .16X) represent the fold increase of antibodies in the
adjuvanted group as compared to TIV (2008–2009) alone.
(TIF)
Figure S5 PapMV nanoparticles improve the humoral
response of TIV (2009–2010). Balb/C mice (5 per group) were
vaccinated twice with a 14-day interval with 1/5 of the human dose
of TIV (2009–2010) adjuvanted with 30 mg PapMV nanoparticles.
The humoral response was analysed by ELISA using serum
collected 14 days after the boost. We measured total IgG titers (A)
and IgG2a titers (B) directed towards TIV (2009–2010). IgG2a
titers directed towards purified recombinant GST-NP (A/WSN/33
(H1N1)) were also measured (C) as well as total IgG titers directed
towards the pandemic influenza vaccine 2009 (D). *** p , 0.001.
Numbers represent the fold increase of antibodies in the adjuvanted
group as compared to TIV (2009–2010) alone.
(TIF)
Figure S6 Immunoblot analysis using 56 peptides (15-
mers overlapping by 5 amino acids and derived from the HA of
the influenza strain WSN/33) exposed to serum of ferrets
immunized with TIV (2009–2010) alone (A) or TIV (2009–2010)
adjuvanted with 150 mg of PapMV nanoparticles (B). The binding
of IgG was revealed with an anti-ferret antibody conjugated to a
fluorescent dye. The fluorescence is showed in black and white in
panels A and B. Panel C shows an overlay of fluorescence
obtained with TIV (2009–2010) treatment stained in red and
fluorescence obtained with the adjuvanted group strained in green
in order to visualize the signals with a better contrast.
(TIF)
Figure S7 Challenge of vaccinated mice with the
heterosubtypic strain A(H1N1) WSN/33. Mice (10 per
group) were vaccinated twice with 1/5 of the human dose of
commercial TIV (2008–2009) from 2 different companies (#1 and
# 2) with or without 30 mg of PapMV nanoparticles. Mice were
challenged with 1LD50 of A(H1N1)/WSN/33 influenza virus 2
weeks after the last boost and were followed for a 14-day period.
A, Body weight of mice, expressed as percentage of initial weight.
B, Symptoms observed on each infected mouse were scored each
day after the challenge. Symptoms: 0. No symptoms. 1. Lightly
spiked fur, slightly curved back. 2. Spiked fur, curved back. 3
Spiked fur, curved back, difficulty in moving and mild dehydra-
tion. 4. Spiked fur, curved back, difficulty in moving, severe
dehydration, closed eyes and ocular secretion.
(TIF)
Figure S8 Long lasting humoral response in mice. Mice (10 per
group) were vaccinated once with 1/5 of the human dose of
commercial TIV (2007–2008) with or without 30 mg of PapMV
nanoparticles. The results presented here refer to the humoral
response 10 months after immunization. A, Total IgG directed to
TIV (2007–2008). B, IgG2a titer directed to TIV (2007–2008), and
C, IgG2a titer directed to WSN/33 GST-NP antigen. Mice were
challenged with 1LD50 of (H1N1) WSN/33 influenza virus, 10
months after the last immunization and were analyzed for a 14-day
period. D) Body weight of mice, expressed as percentage of initial
weight. E) Symptoms (defined in legend to Figure S6) observed on
each infected mouse were scored each day after the challenge.
(TIF)
Figure S9 PapMV nanoparticles induce a CTL response to
conserved influenza proteins when used as an adjuvant in TIV
(2009–2010). Mice (10 per group) were vaccinated twice with 1/5
of the human dose of commercial TIV (2009–2010) with or
without 30 mg of PapMV nanoparticles. To verify the importance
of the CTL response, we depleted CD8+ cells from vaccinated
mice by injecting 0.1 mg of anti-CD8+ antibody. Mice were
challenged with 1LD50 of A(H1N1)/WSN/33 influenza virus 2
weeks after the last immunization and were analyzed for a 14-day
period. A, Body weight of mice, expressed as a percentage of initial
weight. B, Symptoms (defined in legend to Figure S6) observed on
each infected mouse were scored daily after the challenge. C,
Correlation analysis of IgG titer against WSN/33 (H1N1) as a
function of highest body weight loss (%) during the challenge.
(TIF)
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